Starting Material Considerations for iPSC-Derived Cell Products
Time: 2:10 pm
day: Conference Day One
Details:
- Utilizing a risk-based approach to address starting materials, donor eligibility, cell banking and genetic stability
- Implementing phase-appropriate cell collection processes to obtain consistent, compliant, and high-quality starting materials
- Interpreting FDA cGMP guidance for Phase 1 investigational drugs
